Coronary disease & ACSCohort study
Implementation of novel antithrombotic treatment strategies and outcome improvements in patients with myocardial infarction and atrial fibrillation over 20 years: a nationwide cohort study
- nationwide cohort study
Authors' conclusion
Between 2000 and 2021, among patients with MI and AF, we observed reductions in 1-year risks of ischaemic stroke or systemic embolism and CV mortality, occurring during a period of increased prescription of oral anticoagulants, particularly DOACs.
Study context
- Population
- Survivors of an acute myocardial infarction (MI) with atrial fibrillation (AF), SWEDEHEART and national health registries, 2000–2021survivors of an acute MI with AF between 2000 and 2021
- Participants
- 71,513 survivors
- Exposure
- Changes in antithrombotic therapies over time in 2-year cohorts and associations with 1-year outcomes
Main finding
As reported in the abstract
Oral anticoagulant use
Observational data: associations, not effects.
Further findings
Ischaemic stroke or systemic embolism · 1 year
- declined from
- 6.0%
- declined to
- 2.1%
- particularly in the last decade
Cardiovascular (CV) mortality · 1 year
- decreased from
- 19.8%
- decreased to
- 10.5%
Safety
Major bleeding · 1 year
- Major bleeding — increased from
- 3.9%
- Major bleeding: simultaneously with adoption of single rather than dual antiplatelet therapy in combination with DOAC
Original publication
Implementation of novel antithrombotic treatment strategies and outcome improvements in patients with myocardial infarction and atrial fibrillation over 20 years: a nationwide cohort study. Eur Heart J Cardiovasc Pharmacother. Published 27 April 2026. doi:10.1093/ehjcvp/pvag027
Summarised from the published abstract; every number is checked against it